What is Myeloma Phase II MUK five (carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, Velcade and dexamethasone (CVD)?
CATEGORY:
The MUK five trial is a randomized study of cyclophosphamide and dexamethasone in comparison to bortezomib (Velcade®) with cyclophosphamide and dexamethasone.
Save up to 80% off your prescriptions!
How do members experience Myeloma Phase II MUK five (carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, Velcade and dexamethasone (CVD)?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple myeloma | 1 | 0 |
Learn more about our community’s experience with Myeloma Phase II MUK five (carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, Velcade and dexamethasone (CVD)
What are people saying about Myeloma Phase II MUK five (carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, Velcade and dexamethasone (CVD)?
6
6
members have reported taking Myeloma Phase II MUK five (carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, Velcade and dexamethasone (CVD)
Join the conversation and connect with people who have taken Myeloma Phase II MUK five (carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, Velcade and dexamethasone (CVD)
Last updated: